申请人:Ayerst McKenna and Harrison Ltd.
公开号:US04006136A1
公开(公告)日:1977-02-01
A process for preparing 11-deoxyprostaglandin E.sub.1, E.sub.2 and E.sub.3 and analogs thereof is realized by treating an appropriate di(lower)alkyl 3-(optionally substituted)-2-formylcyclopropane-1,1-dicarboxylate with an ylid prepared from a Wittig reagent of formula (AlkO).sub.2 PCCH.sub.2 CO-(c)-CH.sub.3 in which Alk is an alkyl containing one to three carbon atoms and (c) is either (CH.sub.2).sub.q wherein q is an integer from 1 to 6 or cis CH.sub.2 CH=CH(CH.sub.2).sub.r wherein r is an integer from 0 to 3 to obtain the corresponding compound of formula: ##STR1## in which R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl, R.sup.4 is lower alkyl and (c) is as defined herein. The latter compound is reduced with an alkali metal borehydride to yield the corresponding alcohol derivative. Condensation of this alcohol derivative or preferably its corresponding tetrahydropyran-2-yl ether derivative with a triester of formula CH(COOR.sup.6).sub.2 -(a)-(CH.sub.2)pCOOR in which R and R.sup.6 are lower alkyl, (a) is CH.sub.2 CH.sub.2, cis CH=CH or CaC and p is an integer from 2 to 4, gives the corresponding cyclopentanonetriester of formula ##STR2## in which (a), (c), p, R, R.sup.4 and R.sup.6 are as defined herein, R.sup.5 is hydrogen or tetrahydropyran-2-yl, respectively, and R.sup.7 is hydrogen or lower alkyl; the lactonized form of the cyclopentanone-triester being obtained from said alcohol derivative in which R.sup.2 is CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl. In the instance when R.sup.5 is tetrahydropyran-2-yl the cyclopentanonetriester is treated with an acid to give the corresponding compound in which R.sup.5 is hydrogen. The instant compound is then treated with a base under aqueous conditions, followed by optional esterification and acylation to give the desired 11-deoxy-prostaglandin derivatives of the formula ##STR3## in which (a), (c) and p, are as defined herein, (b) is trans CH=CH, R is hydrogen or lower alkyl, R.sup.1 is hydrogen or lower alkanoyl and R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is hydrogen or lower alkanoyl. The derivatives possess prostaglandin-like biological activity and methods for their use are given.
该过程是通过将适当的二(低)烷基3-(可选择取代)-2-甲醛环丙烷-1,1-二羧酸酯与由Wittig试剂制备的具有化学式(AlkO).sub.2PCCH.sub.2CO-(c)-CH.sub.3的偏磷酸酯反应来制备11-去氧前列腺素E.sub.1、E.sub.2和E.sub.3及其类似物。其中,Alk是含有一到三个碳原子的烷基,(c)可以是(CH.sub.2).sub.q,其中q是从1到6的整数,或者是顺式CH.sub.2CH=CH(CH.sub.2).sub.r,其中r是从0到3的整数,从而得到相应的化合物,其化学式为:
在这个化合物中,R.sup.2是氢、低烷基或CH.sub.2OR.sup.3,其中R.sup.3是低烷酰基,R.sup.4是低烷基,(c)如本文所定义。后一种化合物经碱金属硼氢化物还原得到相应的醇衍生物。将这种醇衍生物或更好地是其相应的四氢吡喃-2-基醚衍生物与具有化学式CH(COOR.sup.6).sub.2-(a)-(CH.sub.2)pCOOR的三酯缩合,其中R和R.sup.6是低烷基,(a)是CH.sub.2CH.sub.2、顺式CH=CH或CaC,p是从2到4的整数,得到相应的环戊酮三酯,其化学式为:
其中(a)、(c)、p、R、R.sup.4和R.sup.6如本文所定义,R.sup.5是氢或四氢吡喃-2-基,R.sup.7是氢或低烷基;环戊酮三酯的内酯形式可从上述R.sup.2为CH.sub.2OR.sup.3的醇衍生物中得到,其中R.sup.3是低烷酰基。当R.sup.5为四氢吡喃-2-基时,环戊酮三酯经酸处理得到R.sup.5为氢的相应化合物。然后,将该化合物在水性条件下处理碱,随后进行可选择的酯化和酰化,得到所需的11-去氧前列腺素衍生物,其化学式为:
其中(a)、(c)和p如本文所定义,(b)为顺式CH=CH,R是氢或低烷基,R.sup.1是氢或低烷酰基,R.sup.2是氢、低烷基或CH.sub.2OR.sup.3,其中R.sup.3是氢或低烷酰基。这些衍生物具有类似前列腺素的生物活性,并提供了它们的使用方法。